MicroHeal is pioneering a new era in healthcare with hybrid therapy—combining clinically validated digital therapeutics (DTx) with pharmaceutical interventions (Drug+DTx) to deliver superior outcomes for chronic conditions and disorders management.

We launched Asia’s first clinically validates gut health DTx app, healOgut, empowering patients and providers with hyper-personalized, holistic care for IBS, GERD, Dyspepsia and chronic constipation/diarrhoe. Our hybrid approach (Drug + DTx) is designed to enhance clinical outcomes, patient satisfaction, and long-term disease management.

What sets MicroHeal apart:

- First-mover in clinically validated, prescription digital therapeutics for gut health in India.

- Hybrid therapy model (Drug + DTx) for comprehensive, hyper-personalized care.

-Upcoming launches in oncology, nephrology, urology, and more, targeting complex chronic conditions & disorders.

-Deep-tech integration: leveraging AI/ML, behavioral science, and nutrition for lasting impact.

-Strong partnerships with hospitals, providers, and payers to scale clinically validated hybrid therapy.

-Commitment to “Care Beyond Wall”—empowering patients and clinicians with seamless, digital-first solutions.

At MicroHeal, we’re redefining the future of chronic disease & disorder management—clinically validated solution.

MicroHeal

Org chart

Teams

Offices